These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29941459)

  • 1. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
    Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
    Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
    Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
    Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
    Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
    Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS
    Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway.
    Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R
    Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.
    Felices M; Kodal B; Hinderlie P; Kaminski MF; Cooley S; Weisdorf DJ; Vallera DA; Miller JS; Bachanova V
    Blood Adv; 2019 Mar; 3(6):897-907. PubMed ID: 30890546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
    Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
    Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
    Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
    Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.
    Eksioglu EA; Chen X; Heider KH; Rueter B; McGraw KL; Basiorka AA; Wei M; Burnette A; Cheng P; Lancet J; Komrokji R; Djeu J; List A; Wei S
    Leukemia; 2017 Oct; 31(10):2172-2180. PubMed ID: 28096534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes.
    Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R
    Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.
    Yun HD; Felices M; Vallera DA; Hinderlie P; Cooley S; Arock M; Gotlib J; Ustun C; Miller JS
    Blood Adv; 2018 Jul; 2(13):1580-1584. PubMed ID: 29980573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
    Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
    Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
    Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
    Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.